Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹2,628 Cr
Revenue (TTM)
₹2,797 Cr
Net Profit (TTM)
₹119 Cr
ROE
0.1 %
ROCE
2.3 %
P/E Ratio
22.1
P/B Ratio
0.4
Industry P/E
357.65
EV/EBITDA
7.1
Div. Yield
0 %
Debt to Equity
0.4
Book Value
₹405.1
EPS
₹8.8
Face value
2
Shares outstanding
156,783,095
CFO
₹3,286.95 Cr
EBITDA
₹3,578.22 Cr
Net Profit
₹342.60 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Dishman Carbogen
| -33.1 | -16.4 | -31.6 | -23.8 | 8.2 | 7.2 | -- |
|
BSE Healthcare
| -3.4 | -3.2 | -3.4 | 3.7 | 24.9 | 15.6 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Dishman Carbogen
| -13.2 | 51.1 | 80.1 | -52.9 | 41.8 | 76.7 | -63.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Dishman Carbogen
|
165.7 | 2,627.7 | 2,796.8 | 118.8 | 8.1 | 2.3 | 22.1 | 0.4 |
| 17.0 | 72.6 | 44.6 | -16.6 | -- | 0 | -- | -- | |
| 28.4 | 8.7 | 0.5 | 0.0 | 8.3 | -1.1 | -- | 2.2 | |
| 450.9 | 10,732.6 | 3,262.7 | 439.0 | 15.3 | 16 | 24.4 | 3.6 | |
| 53.1 | 190.1 | 133.8 | -0.3 | -0.7 | -0.6 | -- | 1.9 | |
| 164.8 | 7,497.6 | 2,803.3 | 361.8 | 15.5 | 14 | 20.8 | 2.7 | |
| 1,011.5 | 21,325.1 | 2,169.9 | 332.9 | 20.9 | 15.4 | 64.1 | 9.0 | |
| 4,241.0 | 9,706.6 | 878.4 | 240.1 | 33.8 | 73.3 | 40.4 | 25.3 | |
| 38.1 | 564.1 | 0.0 | 1.6 | -- | -0.5 | 350.6 | 21.0 | |
| 24.7 | 56.3 | 51.4 | 4.5 | 22.0 | 5.2 | 12.5 | 0.6 |
No Review & Analysis are available.
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules... segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP. Read more
Incorporated
2007
Chairman
--
Managing Director
Arpit J Vyas
Group
Dishman Pharma
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Dishman Carbogen Amcis Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Dishman Carbogen Amcis Ltd is ₹165.66 (NSE) and ₹166.15 (BSE) as of 19-Mar-2026 12:04 IST. Dishman Carbogen Amcis Ltd has given a return of 8.18% in the last 3 years.
The P/E ratio of Dishman Carbogen Amcis Ltd is 22.12 times as on 19-Mar-2026, a 94 discount to its peers’ median range of 357.65 times.
The P/B ratio of Dishman Carbogen Amcis Ltd is 0.41 times as on 19-Mar-2026, a 79 discount to its peers’ median range of 1.92 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
1,053.24
|
0.59
|
|
2024
|
0.00
|
0.66
|
|
2023
|
0.00
|
0.34
|
|
2022
|
161.20
|
0.52
|
|
2021
|
0.00
|
0.30
|
The 52-week high and low of Dishman Carbogen Amcis Ltd are Rs 321.95 and Rs 154.47 as of 19-Mar-2026.
Dishman Carbogen Amcis Ltd has a market capitalisation of ₹ 2,628 Cr as on 19-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Dishman Carbogen Amcis Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-6.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.